[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatectomy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,46,81,112,136,165,191,221,250,277,305,327,351,373,397,425,454,480],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643493","eoi-block-vs-tap-block-in-minimally-invasive-hepatectomy-100643493",false,"NCT07615231","EOI Block vs. TAP Block in Minimally Invasive Hepatectomy","External Oblique Intercostal Plane Block and Subcostal Transversus Abdominis Plane Block in Minimally Invasive Hepatectomy: Non-inferiority Trial","EOIvsTAP","Inclusion Criteria:\n\nScheduled to undergo elective robotic or laparoscopic minimally invasive hepatectomy\n\nExclusion Criteria:\n\n* American Society of Anesthesiologists physical status IV or higher\n* History of chronic pain or current use of analgesics, antidepressants, or anticonvulsants for pain management\n* Known hypersensitivity to general anesthetics, opioids, or local anesthetics\n* Conversion to open hepatectomy\n* Requirement for mechanical ventilation for more than 2 hours within 48 hours postoperatively\n* Any other clinical condition that makes the patient unsuitable for participation in the study.","ALL","20 Years","80 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to compare the analgesic efficacy of two different ultrasound-guided nerve blocks-the External Oblique Intercostal (EOI) block and the Subcostal Transversus Abdominis Plane (TAP) block-in patients undergoing minimally invasive hepatectomy. All participants will receive standardized general anesthesia and perioperative care at Seoul National University Hospital. Following anesthesia induction, patients will be randomly assigned to receive either an EOI block or a subcostal TAP block with 0.375% ropivacaine to provide regional pain relief. Postoperative pain will be managed using a combination of scheduled non-opioid analgesics and a fentanyl-based patient-controlled analgesia (PCA) device. The primary objective is to evaluate which regional technique more effectively reduces cumulative opioid consumption during the first 24 hours after surgery. Additionally, the study will assess pain intensity using the Numerical Rating Scale (NRS), the incidence of postoperative nausea and vomiting, and the overall recovery profile, including the time to first ambulation.",[28],"Hepatectomy",[30,31,32],"minimally invasive hepatectomy","TAP block","EOI block","NOT_YET_RECRUITING","2026-06-04",{"date":36,"type":37},"2026-06-08","ACTUAL",{"date":39,"type":22},"2026-06-01",{"date":41,"type":22},"2027-06-30",{"name":43,"class":44},"Seoul National University Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":45},"100639010","reducing-red-blood-cell-transfusion-requirements-for-adults-undergoing-surgical-resection-of-the-liver---a-quality-improvement-project-100639010","NCT07629648","Reducing Red Blood Cell Transfusion Requirements for Adults Undergoing Surgical Resection of the Liver - A Quality Improvement Project","Reducing Red Blood Cell Transfusion Requirements for Hepatectomy - A Quality Improvement Project","Inclusion Criteria:\n\n* Liver resection in this study is defined according to the PRICE-2 trial, involving 3 or more liver segments, such as right posterior sectionectomy (of segments VI and VII) as well as central resections involving segments IVb and V, along with expected blood loss of \\>250 mL\n* in patients with known liver cirrhosis, resection of a full segment was included.\n\nExclusion Criteria (defined according to the PRICE-2 trial):\n\n* current cardiac condition (e.g., MI within the last 6 months, hypertrophic cardiomyopathy, severe valvular disease, or other unstable coronary syndromes)\n* history of cerebrovascular disease (CVA within the past 6 months or severe carotid stenosis with more than 70% occlusion)\n* history of significant peripheral vascular disease (not yet revascularized with regular\u002Fongoing claudication)\n* A current pregnancy\n* A documented, patient-declared refusal to undergo phlebotomy and transfusion\n* preoperative autologous blood donation\n* presence of active infection\n* preoperative hemoglobin \\\u003C100 g\u002FL\n* GFR \\\u003C60 mL\u002Fmin\n* platelets count \\\u003C100 × 109\u002FL\n* Uncorrectable coagulopathies or other decompensated cardiac or respiratory conditions that would contraindicate acute volume depletion\n* undergoing emergency surgery\n* planned intraoperative use of cell salvage\n* inability to participate in follow up\n* in the case of repeat liver resections, previous participation in the trial","18 Years",{"count":55,"type":22},60,"OBSERVATIONAL","The goal of this clinical trial is to determine if implementing a controlled blood removal protocol (i.e. hypovolemic phlebotomy \\[HP\\] where approximately 10% of the patient's blood is removed and reinfused following hepatic resection as described in the PRICE-2 clinical trial) will reduce the rate of blood transfusions in liver resection surgery at Kingston Health Sciences Centre. Our goals (not included in the PRICE-2 trial) are as follows:\n\n* Improved monitoring of how the body responds during surgery following controlled blood removal. We will conduct blood tests to look at oxygen, carbon dioxide, lactate, and acid (pH) levels in the blood as well as urine output.\n* Standardized guidelines for how fluids and blood pressure medications are used during surgery to reduce blood loss and keep hemodynamics stable.\n* Monitor patients' recovery following surgery to track complications, injury to the heart, length of hospital stay, and outcomes for up to 90 days. We will also compare long-term recurrence rate of liver cancer compared to patients in the past at our site who did not receive the controlled blood removal (i.e., HP) prior to surgery.",[28,59,60,61,62,63],"Transfusion Requirements","Intraoperative Bleeding","Intraoperative Monitoring","Blood Cells Transfusion","Phlebotomy",[65,66,67,68,69,70,71,72],"hypovolemic phlebotomy","hepatectomy","Perioperative Care","erythrocyte transfusion","liver resection","transfusion requirements","therapeutic phlebotomy","intraoperative bleeding",{"date":74,"type":37},"2026-06-05",{"date":76,"type":22},"2026-06",{"date":78,"type":22},"2031-06",{"name":80,"class":44},"Dr. Glenio Mizubuti (MD, PhD, FRCPC)",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100638283","phase-4-intravenous-lidocaine-for-hepatectomy-100638283","NCT07590830","Intravenous Lidocaine for Hepatectomy","Effect of Perioperative Intravenous Lidocaine on Postoperative Opioid Related-side Effects After Open HEPatectomy: a Multicentre Prospective Randomized Controlled Study","ILHEP","Inclusion Criteria:\n\n* Inclusion criterion 1 : Age ≥ 18 years\n* Inclusion criterion 2 : Undergoing a scheduled surgery for open hepatectomy\n* Inclusion criterion 3 : Effective contraception in accordance with CFTG recommendations\n* Inclusion criterion 4 : Having received oral and written information about the protocol and having signed a consent form to take part in this research\n* Inclusion criterion 5 : Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Exclusion criterion 1 : Weight \\> 100 kg\n* Exclusion criterion 2 : Allergy or contraindication to lidocaine or one of its excipients and, in particular:\n\n  * Known hypersensitivity to lidocaine hydrochloride, to amide-type local anesthetics, or to any of the excipients (sodium chloride, sodium hydroxide solution or concentrated hydrochloric acid solution, water for injection)\n  * Treatment with following antiarythmic medication : class I, class III or Sotalol\n  * Heart failure NYHA grade 3-4, AV-block \\>1, without pacemaker\n  * Acute porphyria\n  * Recurrent porphyrias\n  * Uncontrolled epilepsy \u002F Seizure at enrollment\n* Exclusion criterion 3 : Allergy to one of the drugs used for anaesthesia or one of their excipients\n* Exclusion criterion 4 : Nefopam contraindication and, in particular:\n\n  * Renal insufficiency (Creatinine clearance \\\u003C 15 mL\u002Fmin)\n  * Untreated glaucoma\n  * Uncontrolled epilepsy\n  * Allergy\n* Exclusion criterion 5 : Ketoprofen contraindication and, in particular:\n\n  * Renal insufficiency (Creatinine clearance \\\u003C 50 mL\u002Fmin)\n  * Inflammatory bowel disease\n  * Allergy\n* Exclusion criterion 6 : Urgent surgery\n* Exclusion criterion 7 : Transplant surgery or transplanted patients\n* Exclusion criterion 8 : Surgery with planned regional anaesthesia\n* Exclusion criterion 9 : Patient with a preoperative Sp02 \\\u003C 95%\n* Exclusion criterion 10 : Obstructive sleep apnea syndrome\n* Exclusion criterion 11 : Severe hepatic insufficiency (Prothrombin Ratio \\\u003C 15%)\n* Exclusion criterion 12 : Patient with an ongoing opioid medication that will blur the results\n* Exclusion criterion 13 : Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty, pregnant or breast-feeding women, minors, persons unable to express their consent, persons hospitalized for a different reason\n* Exclusion criterion 14 : Known participation in other interventional research (RIPH1 or RIPH2)",{"count":90,"type":22},312,[92],"PHASE4","Liver resection is increasingly performed for hepatic tumors, mainly primary liver cancers and resectable metastases, but also for some benign lesions. Postoperative pain is often significant, regardless of the surgical technique, making effective pain control essential to promote early mobilization and reduce complications.\n\nCurrent standard care relies on multimodal analgesia, combining several drugs administered during surgery, with morphine administered as rescue therapy when required. Morphine is associated with side effects such as nausea, vomiting, ileus, hypoxemia, opioid-induced hyperalgesia, and transient cognitive impairment. Therefore, there is a need to optimize pain management while reducing opioid consumption and related adverse effects.\n\nIntravenous (IV) lidocaine has well-documented anti-inflammatory effects and is effective against neuropathic pain. Several studies have shown that intravenous lidocaine may be associated with improved analgesia, reduced opioid consumption, shorter hospital stay, and decreased postoperative ileus, nausea, and vomiting-particularly in abdominal and genitourinary surgeries. Therefore, Intravenous (IV) lidocaine may be a valuable alternative for postoperative pain management after liver surgery.\n\nNational guidelines now recommend perioperative Intravenous (IV) lidocaine for abdominal surgeries but its efficacy in liver surgery has not yet been established due to a lack of specific evidence (more specific data are needed). Findings from other types of abdominal surgery suggest a potential benefit, which should be confirmed by dedicated clinical trials and robust multicenter evaluation such as the ILHEP protocol.\n\nThe goal of this clinical trial is to assess the effect of intravenous perioperative lidocaine on postoperative opioid related-side effects and to formally confirm the safety of lidocaine during hepatic surgical procedures. The hypothesis is that Intravenous (IV) lidocaine compared with placebo (a look-alike substance that contains no drug e.g. a saline solution) would improve postoperative outcome by reducing opioid related side-effects in patients undergoing liver surgery and benefitting of the same baseline analgesia.\n\nIn the context of this trial, patients will receive either intravenous lidocaine or placebo according to their assigned randomization group during standardized general anesthesia, and will then be followed throughout their hospital stay until discharge or up to a maximum of 28 days.\n\nAn ancillary study will be conducted in patients enrolled at the coordinating center in Rennes to assess exposure to lidocaine during intravenous administration and to evaluate the relationship between blood concentrations and adverse events.",[28],[96,97,98,99,100,28,101],"Lidocaine","Pain management","Analgesics","Postoperative opioid related-side effects","Double-Blind Method","Anesthesia","2026-05-12",{"date":104,"type":37},"2026-05-15",{"date":106,"type":22},"2026-08-01",{"date":108,"type":22},"2028-09-01",{"name":110,"class":44},"Rennes University Hospital",9,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":45},"100634275","preoperative-oncogeriatric-assessment-in-patients-undergoing-hepatectomy-100634275","NCT07537569","Preoperative Oncogeriatric Assessment in Patients Undergoing Hepatectomy","Impact of Preoperative Oncogeriatric Assessment in Elderly Patients Undergoing Surgery for Hepatectomy","Inclusion Criteria:\n\n* Patients aged ≥ 70 years\n* Diagnosed hepatic malignancies requiring hepatectomy\n* Eligible for curative surgery as determined by multidisciplinary team\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Ineligibility for surgery due to advanced disease or severe comorbidities\n* Severe cognitive impairment (MMSE score \\\u003C 18)\n* Refusal to participate","70 Years",{"count":121,"type":22},242,[25],"This study aims to bridge the gap between geriatric medicine and surgical oncology. The findings will provide valuable insights into optimizing perioperative care for older adults, enhancing surgical safety, and improving long-term recovery trajectories, thereby supporting a more patient-centered, multidisciplinary approach in the management of elderly patients undergoing hepatectomy",[125,126,28],"Hepatic Malignancies","Comprehensive Geriatric Assessment","2026-04-16",{"date":129,"type":37},"2026-04-17",{"date":131,"type":22},"2026-04",{"date":133,"type":22},"2029-09",{"name":135,"class":44},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":153,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":45},"100632301","routine-intraoperative-white-test-for-bile-leak-detection-in-liver-resection-100632301","NCT07511907","Routine Intraoperative White Test for Bile Leak Detection in Liver Resection","Routine White Test for Early Detection of Bile Leak in Elective Liver Resection - A Study Protocol for Randomized Controlled Trial (DELiveR Trial).","DELiveR","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Undergoing elective liver surgery (regardless its modality): a) major hepatectomy OR b) minor hepatectomy (anatomic liver resection or non-anatomic liver resection).\n* Possibility of performing the WT: intraoperative, simultaneous cholecystectomy or prior cholecystectomy with identifiable cystic stump allowing bile duct access.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Undergoing intraoperative hepaticojejunostomy.\n* Previous cholecystectomy without accessible cystic stump.\n* Unresectable disease found intraoperatively.\n* Allergy to SMOFlipid 5% components.\n* Pregnancy or lactation.\n* Emergency liver resection.\n* Refusal for participation in trial.",{"count":145,"type":22},260,[25],"Bile leakage (BL) remains one of the most frequent complications following liver resection and is associated with increased postoperative morbidity and mortality, higher reintervention rates, prolonged hospital stay, and increased healthcare costs. Effective intraoperative identification and closure of open bile ducts may reduce the risk of postoperative BL. The White Test, which involves retrograde injection of a lipid emulsion into the biliary tree, enables active detection of bile leaks during surgery; however, its routine use has not been established in randomized clinical trials across all types of liver resection.\n\nThis is a single-center, prospective, randomized, parallel-group, single-blinded superiority trial designed to evaluate the effectiveness of routine intraoperative use of the White Test compared with standard intraoperative bile leak detection using a white gauze test. Adult patients undergoing elective liver resection (major or minor, including both anatomic and non-anatomic resections) who meet eligibility criteria will be enrolled after providing written informed consent.\n\nParticipants will be randomized in a 1:1 ratio to either the intervention group (White Test) or the control group (standard gauze test), using stratified block randomization according to the type of resection (major vs minor). Allocation will be concealed using sequentially numbered, opaque, sealed envelopes. Patients will remain blinded to group assignment, while the operating surgeon cannot be blinded due to the nature of the intervention.\n\nIn the intervention group, following completion of liver parenchymal transection and achievement of hemostasis, the cystic duct stump will be identified and cannulated. The distal bile duct will be temporarily occluded, and 10-20 mL of lipid emulsion will be injected retrogradely into the biliary tree. The transection surface will be inspected for leakage of the white emulsion. Identified leaks will be managed by ligation or suturing, and the test may be repeated until no further leakage is observed. In the control group, bile leak detection will be performed by applying sterile white gauze to the transection surface with visual inspection, followed by suturing of identified leaks as needed.\n\nAll patients will have intra-abdominal drainage placed at the resection site. Drain fluid bilirubin concentration will be measured on postoperative day three. Patients will be followed for 30 days after surgery.\n\nThe primary outcome is the incidence of postoperative bile leakage within 30 days, defined according to the International Study Group of Liver Surgery (ISGLS) criteria. Secondary outcomes include severity of bile leakage (ISGLS grades A-C), postoperative morbidity (Clavien-Dindo classification), need for postoperative interventions (endoscopic, radiological, or surgical), intensive care unit (ICU) admission and length of ICU stay, and total hospital length of stay.\n\nThe primary analysis will follow the intention-to-treat principle and will be performed separately within strata defined by resection type (major vs minor). Secondary and subgroup analyses will be considered exploratory. No formal interim analysis is planned; however, patient safety will be continuously monitored throughout the study.\n\nThe results of this trial are expected to clarify the role of routine intraoperative White Test in liver surgery and its potential to reduce postoperative bile leakage and improve clinical outcomes.",[149,150,151,28,152],"Bile Leak","Bile Leakage","Liver Resection","Bile Duct Disorder",[69,66,154,155],"bile ducts","white test","2026-04-11",{"date":158,"type":37},"2026-04-15",{"date":160,"type":22},"2026-06-15",{"date":162,"type":22},"2028-10-01",{"name":164,"class":44},"Medical University of Warsaw",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100631973","phase-3-a-study-of-methylprednisolone-in-people-having-liver-surgery-100631973","NCT07507643","A Study of Methylprednisolone in People Having Liver Surgery","A Randomized Controlled Trial of Methylprednisolone Versus Standard of Care in Patients Undergoing Major Hepatectomy","Inclusion Criteria:\n\n* Age ≥18 years at the time of consent.\n* Scheduled to undergo elective major hepatectomy (defined by CPT codes 47122 \\[trisegmentectomy\\], 47125 \\[total left hepatectomy\\], or 47130 \\[total right hepatectomy\\]).\n* In addition to major hepatectomy, as defined above, patients may undergo additional partial hepatectomy or operative ablation.\n\nExclusion Criteria:\n\n* Known or documented adverse reactions to methylprednisolone.\n* Unable to receive methylprednisolone because of coexisting medical conditions.\n* Long-term (≥10-day course) systemic corticosteroid use, regardless of dose, if doses have been administered within 30 days of the planned date of surgery. This will not apply to steroids administered, in accordance with the standard of care, with preoperative chemotherapy. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive-airway diseases), eye drops, and local injections (e.g., intra-articular).\n* Significant chance (based on surgeon judgement) of being unable to successfully complete surgery because of unresectability.\n* Expected or highly likely to undergo concomitant major organ resection (stomach, pancreas, colon, rectum, uterus, ovaries, bladder, kidney, small bowel).\n* Expected or highly likely to undergo biliary tree reconstruction via creation of a biliary-enteric anastomosis.\n* Scheduled to undergo concurrent insertion of a hepatic artery infusion pump device.\n* Estimated renal dysfunction defined by any of the following: creatinine clearance\n\n  ≤40 mL\u002Fmin as calculated by the Cockcroft-Gault Equation, currently on hemodialysis, currently on peritoneal dialysis.\n* Dependence on mechanical ventilation before surgery.\n* Pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.\n* Known at the time of enrollment to have a bacterial infection that is expected to be present at the time of surgery or receipt of systemic antibiotic or antifungal therapy within 7 days before surgery.\n* Unable to provide informed consent",{"count":173,"type":22},750,[175],"PHASE3","The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.",[28],[28,179,180,181],"Methylprednisolone","Memorial Sloan Kettering Cancer Center","26-077","RECRUITING","2026-03-27",{"date":185,"type":37},"2026-04-02",{"date":183,"type":37},{"date":188,"type":22},"2029-03-27",{"name":180,"class":44},19,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":45},"100340668","spinal-anesthesia-for-enhanced-recovery-after-liver-surgery-100340668","NCT03715517","Spinal Anesthesia For Enhanced Recovery After Liver Surgery","Spinal Anesthesia for Enhanced Recovery After Liver Surgery","SAFER-L","Inclusion Criteria:\n\n* Male or female, Adults aged ≥ 18 years (there will be no upper age restriction);\n* American Society of Anesthesiologists Physical Status classification (ASA-PS) of I to III;\n* Undergoing subcostal or midline laparotomy for elective liver resection surgery under general anesthesia; if the planned procedure is a combined operation (i.e., concomitant extrahepatic surgery) , the associated procedure should not add more than one hour to the surgical time of the primary hepatic resection procedure alone;\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Provision of signed and dated informed consent form\n* Body mass index (BMI) between 17 and 40 kg·m-², inclusive;\n* Negative result on serum pregnancy test at Screening and negative urine pregnancy test at Baseline (for women of childbearing potential, defined as those who have not undergone a hysterectomy or been postmenopausal for at least 12 consecutive months); and not currently breastfeeding, or planning to do so within 7 d following surgery;\n* Stated willingness and ability to comply with all study and\u002For follow-up evaluations and communicate clearly with the Investigator and staff; and\n* Voluntary participation and ability to provide written informed consent prior to any study procedures.\n\nExclusion Criteria:\n\n* Emergency surgery;\n* Age \\\u003C 18 years;\n* Planned laparoscopic hepatic resection;\n* Planned laparotomy incision other than (right) subcostal, midline, or extended midline;\n* Patients with obvious non-resectable disease prior to signing informed consent;\n* Liver transplant recipient or previous hepatic resection or living-donor hepatectomy surgery;\n* Major surgery (open abdominal and\u002For thoracic) under general anesthesia ≤ 30 d preoperatively;\n* Contraindications to neuraxial (spinal or epidural) anesthesia: (a) anticipated difficult intubation; (b) coagulation or hemostatic abnormalities within 30 d of surgery (defined as thrombocytopenia \\[platelet count \\\u003C 100 × 10⁹ L-¹\\]; INR \\> 1.4; or activated partial thromboplastin time \\[aPTT\\] \\> 40 s); (c) bleeding diathesis; (d) ongoing use (≤ 7 d before surgery) or planned perioperative use of antiplatelet agents (apart from acetylsalicylic acid 81 mg) or anticoagulants (excluding deep-vein thrombosis prophylaxis); (e) recent (≤ 30 d preoperatively) systemic infection or current (≤ 48 h) fever (≥ 38.4 °C), or evidence of infection (including superficial cutaneous infection in the thoracic and\u002For lumbar regions); (f) history of neurologic disorder affecting the spinal cord or the hemithorax or below; or impaired bladder\u002Fbowel function; (g) acute or subacute (≤ 90 d preoperatively) intracranial hemorrhage; or (h) technical contraindications to epidural placement: (i) local skin or soft tissue infection at proposed site for thoracic epidural insertion; (ii) previous cervicothoracic, thoracic, or thoracolumbar spinal surgery; (iii) history of spinal tumor, fracture or infection; or (iv) recent (≤ 14 d preoperatively) epidural corticosteroid injection;\n* Significant cardiac arrhythmias (including pacemaker-dependence) or clinically significant cardiovascular disease (New York Heart Association \\[NYHA\\] functional classification III-IV);\n* Volume overload (hyperhydration), particularly in cases of pulmonary edema or acute decompensated congestive heart failure (CHF);\n* Acute kidney injury (AKI) and\u002For chronic kidney disease (CKD) based on the 2012 Kidney Disease Improving Global Outcomes (KDIGO) AKI (excluding the oliguria criterion) and CKD guideline definitions: AKI: increase in serum creatinine (SCr) (≥ 26.5 μmol·L-¹ within 48 h or ≥ 1.5× baseline within 7 d); CKD: abnormalities of kidney structure or function, present for \\> 3 mo, defined as either of the following present for \\> 3 mo: (1) ≥ 1 marker(s) of kidney damage: (a) albuminuria (24-h albumin-creatinine ratio \\[ACR\\] ≥ 30 mg·g-¹ \\[≥ 3 mg·mmol-¹\\]), (b) urine sediment abnormalities, (c) electrolyte and other abnormalities due to tubular disorders, (d) abnormalities detected by histology, (e) structural abnormalities detected by imaging, (f) history of kidney transplantation; and\u002For decreased glomerular filtration rate (GFR \\\u003C 60 mL-¹·min-¹·1.73 m-², estimated using the 2009 CKD-EPI creatinine equation \\[eGFR\\_creat\\]);\n* Severe hypernatremia (\\[Na⁺\\] ≥ 155 mmol·L-¹) and\u002For hyperchloremia (\\[Cl-\\] ≥ 125 mmol·L-¹);\n* Chronic pain; current (≤ 30 d preoperatively) and\u002For prior chronic (for a period of ≥ 90 d) opioid use; or history of alcohol, opiate, and\u002For other drug abuse or dependence;\n* Use of supraphysiologic glucocorticoid (GC) doses (≥ 7.5 mg·day-¹ of prednisone or equivalent): recent (≤ 30 d), prolonged (\\> 2 consecutive weeks), or multiple courses totalling \\> 3 weeks in the preceding 6 months;\n* Known allergy or sensitivity (e.g., glucose-6-phosphate dehydrogenase \\[G6PD\\] deficiency) to amide local anesthetics, opioids, or acetaminophen, or hypersensitivity to other materials to be used in the study (e.g., latex \\[epidural catheter adapter\\], epidural dressing or tape); or\n* Altered mental status or educational, psychiatric, or communication (language, literacy) barriers that would impede accurate assessment of postoperative pain and\u002For ability to complete questionnaire instruments.",{"count":200,"type":22},128,[25],"This project proposes to compare epidural versus spinal anesthesia in patients having liver resection surgery. The investigators hypothesize that spinal anesthesia will result in improved blood pressure control postoperatively and reduce the amount of intravenous fluids required after surgery. Spinal anesthesia is expected to provide the same pain control benefits as epidurals, with faster recovery of function. Spinal anesthesia may be a simple and effective way to improve and enhance the recovery in the increasing number of patients requiring liver resection.",[28,204,205],"Pain, Postoperative","Liver Neoplasms",[207,208,209,210,211],"Injections, Spinal","Analgesia, Epidural","Anesthesia, Spinal","Patient Reported Outcome Measures","Postoperative Period","2026-02-03",{"date":214,"type":37},"2026-02-05",{"date":216,"type":37},"2018-10-04",{"date":218,"type":22},"2031-12-31",{"name":220,"class":44},"University of Manitoba",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":231,"conditions":232,"keywords":235,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":45},"100622584","the-use-of-artificial-intelligence-for-the-prediction-of-recurrence-after-resection-of-colorectal-liver-metastases-100622584","NCT07385521","The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases","A Retrospective Observational Study to Use Artificial Intelligence for Prediction of Disease REcurrence of COlorectal Cancer Liver METastasis After Hepatic Resection","AI-RECOLMET","Inclusion Criteria:\n\n* Pathologically confirmed diagnosis (at final pathology) of liver metastases from colon or rectal adenocarcinoma\n* \\> 6 months of follow-up\n* no other concomitant neoplastic disease\n\nExclusion Criteria:\n\n* All subjects receiving hepatic resection but not fulfilling the inclusion criteria",{"count":230,"type":22},1000,"Colorectal cancer is the third most common cancer worldwide and the fourth most common cause of cancer-related death. Survival is primarily determined by stage of disease and the presence of metastases. The combination of chemotherapy and liver resection remains the treatment option with the highest survival benefit for patients with liver metastases from colorectal cancer, with surgery still being the only recognized potential curative treatment; surgical locoregional treatment can also be combined with thermal ablation to enhance the possibility of complete liver clearance. Despite significant improvements in prognosis, a large proportion of patients (almost half) will still experience recurrence following treatment. There is a clinical need to identify a priori patients who are different likely to develop disease recurrence after locoregional treatment (liver resection ± thermal ablation) and to respond differently to chemotherapy, in order to refine risk-based allocation of treatments and resources. Widespread digitalization of healthcare generates a large amount of data, and together with today accessible high-performance computing, artificial intelligence technologies can be applied to overcome the current limitations in estimating colorectal cancer liver metastases recurrence and response to locoregional and chemotherapy treatments, thus achieving better treatment allocation than current practice. All radiomic features can also help in training the neural network aimed at detecting liver metastases before they become visually detectable by the radiologist. Therefore, this study aims to evaluate whether a multifactorial machine learning model (including clinical and radiomic) can identify patients with colorectal cancer liver metastases with a high risk of progression after chemotherapy and recurrence after liver resection",[233,151,28,234],"Colorectal Liver Metastasis (CRLM)","Liver Ablation",[236,237,28,238,239,240],"Colorectal liver metastases","Liver resection","Liver ablation","Machine learning (ML)","Artificial Intelligence (AI)","2026-01-29",{"date":243,"type":37},"2026-02-04",{"date":245,"type":37},"2025-02-19",{"date":247,"type":22},"2027-02-19",{"name":249,"class":44},"Francesco De Cobelli",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":264,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":45},"100618877","ultrasound-guided-external-oblique-intercostal-plane-block-versus-erector-spinae-block-for-post-hepatectomy-pain-100618877","NCT07337330","Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Block for Post Hepatectomy Pain","Comparative Study Between Ultrasound Guided External Oblique Intercostal Plane Block and Erector Spinae Block for Postoperative Analgesia in Hepatectomy Incision in Cancer Patients","Inclusion Criteria:\n\n* Cancer patients undergoing hepatectomy under general anaesthesia\n* Aged 18 years or older\n* ASA II \\& III\n* BMI \\>20kg\u002Fm2 and \\\u003C35kg\u002Fm2\n\nExclusion Criteria:\n\n* History of psychiatric disorders or history of major depression.\n* Major medical conditions (heart failure , chronic kidney disease ,patient on dialysis)",{"count":258,"type":22},52,[25],"Management of acute post-operative pain has received keen attention in recent years with considerable concurrent advancement in the field.\n\nThe importance of effective pain relief has long been realised, and acute pain services (APS) are operational in majority of the hospitals in the developed world for decades.\n\nPostoperative pain following abdominal surgery if severe enough may cause several side effects as \"splinting, hypoventilation, atelectasis, immobility, hypercoagulability, thromboembolic events, vasoconstriction, tachycardia, increased systemic vascular resistance, dysrhythmias and cardiac ischemia in susceptible patients, insomnia, anxiety, feeling of helplessness\".\n\nUltrasound-guided fascial plane blocks have been rapidly incorporated into regional anaesthesia practice in recent years as an alternative to neuraxial techniques and involve injection into a tissue plane to provide analgesia in various anatomic areas.\n\nExternal oblique intercostal plane block (EOIPB) is a novel block, which has been described as an important modification of the fascial plane blocks that can consistently involve the upper lateral abdominal walls.\n\nThe erector spinae plane (ESP) block is a new regional aesthetic technique that can be used to provide analgesia for a variety of surgical procedures or to manage acute or chronic pain. The technique is relatively easy to perform on patients.\n\nThe ESPB involves injection of local anaesthetic in the erector spinae fascial plane, superficial to the tip of the transverse process of the vertebra and deep to the erector spinae muscle.",[262,28,263],"Pain; Cancer","Nerve Block",[66,265,266,267,268],"erector spinae block","external oblique intercostal plane block","liver cancer","ultrasound guided",{"date":270,"type":37},"2026-02-02",{"date":272,"type":22},"2026-01-15",{"date":274,"type":22},"2026-09-15",{"name":276,"class":44},"National Cancer Institute, Egypt",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":283,"targetDuration":285,"studyType":56,"phases":4,"briefSummary":286,"conditions":287,"keywords":291,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100622362","clinical-trial-protocol-for-evaluating-the-efficacy-and-safety-of-thoracoabdominal-endoscopic-surgery-system-in-remote-laparoscopic-surgery-for-urology-general-surgery-gynecology-and-thoracic-surgery-100622362","NCT07382635","Clinical Trial Protocol for Evaluating the Efficacy and Safety of Thoracoabdominal Endoscopic Surgery System in Remote Laparoscopic Surgery for Urology, General Surgery, Gynecology and Thoracic Surgery","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 80 years;\n* Patients confirmed by investigators eligible for surgeries in urology (e.g., partial nephrectomy (transperitoneal\u002Fretroperitoneal), radical prostatectomy, pyeloplasty, etc.), general surgery (e.g., distal\u002Fradical total gastrectomy for gastric cancer, radical resection for colorectal cancer, hepatectomy\u002Fsplenectomy, etc.), gynecology (e.g., radical hysterectomy plus pelvic lymphadenectomy, etc.) and thoracic surgery (e.g., segmental\u002Flobectomy, radical esophagectomy, etc.).\n* Subjects voluntarily participate in the clinical trial, and subjects or their guardians give informed consent and sign the informed consent form.\n* Willing to cooperate with and complete trial follow-ups and relevant examinations.\n\nExclusion Criteria:\n\n* Need for emergency surgery (e.g. gastric cancer, colorectal cancer combined with perforation, bleeding, obstruction, etc.);\n* With other malignancies or a previous history of other malignancies.\n* Preoperative imaging suggests that the tumour has distant metastases.\n* The patient has a history of relevant surgery or previous history of other malignancy and is judged by the investigator to be unsuitable for enrolment.\n* Severe bleeding tendencies or coagulopathic disorders.\n* With long-term use of anticoagulant and anti-platelet drugs (anti-platelet aggregation drugs discontinued less than 1 week prior to surgery), history of bleeding disorders or hematopoietic or coagulation disorders.\n* Significant immunodeficiency due to underlying illness (e.g. HIV\u002FAIDS) and\u002For medication (e.g. systemic corticosteroids).\n* Other conditions which, in the opinion of the investigator, make participation in this trial inappropriate.",{"count":284,"type":22},98,"1 Month","Evaluation of the Efficacy and Safety of the Thoracoabdominal Endoscopic Surgery System Produced by Shenzhen Cornerstone Robotics Technology Co., Ltd. in Remote Laparoscopic Surgeries for Urology, General Surgery, Gynecology and Thoracic Surgery",[288,289,28,290],"Colorectal Cancer","Esophageal Cancer","Radical Hysterectomy",[292,293,294,66,295],"distal gastric cancer","radical surgery","colorectal cancer","radical hysterectomy","2026-01-27",{"date":212,"type":37},{"date":299,"type":22},"2026-02-01",{"date":301,"type":22},"2027-08-01",{"name":303,"class":304},"Cornerstone Robotics","INDUSTRY",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":45},"100597737","ai-based-prediction-of-hcc-recurrence-patterns-after-resection-apar-100597737","NCT07062380","AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)","Prospective Validation of Multimodal Deep Learning Models for Predicting Recurrence Patterns in Early-Stage Hepatocellular Carcinoma After Resection: A Natural Treatment Cohort Stratification Study","Inclusion Criteria:\n\n* Aged 18-75 years, regardless of gender.\n* BCLC stage 0-A, scheduled for curative liver resection.\n* Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).\n* Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.\n* Child-Pugh liver function score ≤7.\n* ECOG Performance Status (PS) 0-1.\n* No severe organic diseases of the heart, lungs, brain, or other vital organs.\n\nExclusion Criteria:\n\n* Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).\n* Postoperative pathology confirms non-HCC diagnosis.\n* Pregnant or lactating women.\n* History of organ transplantation.\n* Inability to comply with the study protocol or follow-up schedule.","75 Years",{"count":314,"type":22},353,"This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.\n\nThe main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.",[317,28],"Hepatecellular Carcinoma","2025-08-26",{"date":320,"type":37},"2025-09-03",{"date":322,"type":37},"2025-06-10",{"date":324,"type":22},"2028-06-10",{"name":326,"class":44},"Tongji Hospital",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":312,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100589640","intertransverse-process-block-for-quality-of-recovery-post-open-hepatectomy-100589640","NCT06957041","Intertransverse Process Block for Quality of Recovery Post-Open Hepatectomy","Effect of Intertransverse Process Block on the Quality of Recovery Post-Open Hepatectomy: A Pilot Non-Randomised Study of Intervention","ITPB QoR","Inclusion Criteria:\n\n\\- Adult patients aged 18-75 years of ASA I - III physical status classification undergoing open hepatectomy for benign or malignant liver lesion.\n\nExclusion Criteria:\n\n* Patient refusal\n* Patients who are unable to comprehend the QoR15 form\n* Local or systemic infection\n* Coagulopathy leading to absolute contraindication to regional anesthesia\n* Contraindication to local anaesthetics (LA) such as LA allergy",{"count":336,"type":22},20,[25],"The study aims to assess the analgesic efficacy of the ITPB at the retro-SCTL space in patients undergoing major open hepatectomy surgery. This is assessed by:\n\nPrimary Objective:\n\nPrimary outcome measure:\n\n● Assessing the quality of recovery 15 (QoR15) score at 24 and 48 hours\n\nSecondary outcome measure:\n\n* Number of anaesthetic and hypoesthetic dermatomes on the ventral and dorsal aspect of the thorax on both the sides at 30 minutes of block completion and during the post anaesthetic room (PACU) discharge\n* Assessing the 24-hour area under the curve of postoperative pain numerical rating score (NRS, 0-10) at rest and deep breathing or upon use of triflow.\n* Assessing the amount of postoperative morphine (mg) equivalent consumption at 24 and 48 hours\n* Time to discharge from High dependency unit (HDU) or Intensive care unit (ICU)\n\nHypothesis:\n\nThe investigators hypothesize that the application of ITPB targeting the retro-SCTL space in patients undergoing open hepatectomy will improve overall quality of recovery and pain score.",[28,340,341],"Intertransverse Process Block","Quality of Recovery (QoR-15)","2025-04-25",{"date":344,"type":37},"2025-05-04",{"date":346,"type":22},"2025-05-01",{"date":348,"type":22},"2026-10-01",{"name":350,"class":44},"Chinese University of Hong Kong",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":45},"100589162","textbook-outcomes-of-right-hemihepatectomy-in-patients-with-hepatocellular-carcinoma-100589162","NCT06950827","Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma","Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma: a Comparative Study of Laparoscopic and Open Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. The lesion is limited to the right half of the liver and diagnosed as hepatocellular carcinoma based on paraffin pathology and immunohistochemistry results;\n3. The type of surgery is elective surgery;\n4. The patient's preoperative liver function was Child Pugh A or B grade, and the preoperative ASA (American Society of Anesthesiologists) rating was I, II, or III.\n\nExclusion Criteria:\n\n1. Pathological confirmed cholangiocarcinoma, mixed cell carcinoma, or extrahepatic metastatic malignant tumors;\n2. Previous history of upper abdominal surgery;\n3. Simultaneously undergoing adjacent abdominal organ resection, major vessel and biliary reconstruction surgery, except for the gallbladder;\n4. Merge adjacent organ invasions except for the gallbladder, with main blood vessels, bile duct cancer emboli, or distant metastases;\n5. Lost to follow-up or loss of primary clinical data.",{"count":359,"type":22},400,"Although traditional open right hemihepatectomy is a mature technique, the incision is usually very large; Intraoperative bleeding may be excessive, and postoperative liver failure is also prone to occur. In recent years, compared with traditional open surgery, laparoscopic surgery has many advantages, such as smaller surgical incision and faster postoperative recovery. In recent years, more and more centers have gradually transitioned to performing right hemihepatectomy through laparoscopy as much as possible. However, due to the difficulty of the surgery, steep learning curve, and postoperative complications, its adoption is limited to high-capacity surgical centers. Despite significant progress in laparoscopic liver resection technology, its clinical efficacy remains controversial, especially in laparoscopic right hemihepatectomy. More research is needed to confirm the feasibility and safety of this surgery. At present, it is unclear whether there is a difference in textbook outcomes (TO) between HCC patients undergoing open and laparoscopic right hemihepatectomy, and the association between TO and patient survival prognosis.",[362,28,363],"Hepatocellular Carcinoma","Laparoscopic Hepatectomy","2025-04-22",{"date":366,"type":37},"2025-04-30",{"date":368,"type":37},"2025-04-05",{"date":370,"type":22},"2025-05-15",{"name":372,"class":44},"West China Hospital",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":386,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":45},"100572182","diagnostic-value-of-next-generation-sequencing-analysis-in-biliary-tract-tumours-100572182","NCT06729944","Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours","Inclusion Criteria:\n\n* Availability of enough tissue for histological and NGS analysis (at least 20 ng DNA).\n* Age greater than\u002Fequal to 18 years.\n\nExclusion Criteria:\n\n* None",{"count":380,"type":22},50,[25],"The aim of this study is to identify a dysplasia- and CCA-specific NGS panel to increase the diagnostic sensitivity of histological and\u002For cytological examination of biliary tract stenosis.",[28,384,385],"NGS","Stenosis of Bile Duct",[387,388],"Next Generation Sequencing","Stenosis of bile duct","2024-12-10",{"date":391,"type":37},"2024-12-12",{"date":393,"type":37},"2023-04-27",{"date":76,"type":22},{"name":396,"class":44},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":45},"100519543","multimodal-image-registration-for-helping-laparoscopic-liver-surgery-guidance-100519543","NCT06044909","Multimodal Image Registration for Helping Laparoscopic Liver Surgery Guidance","IMMORTALLS","Inclusion Criteria:\n\n* Patients undergoing hepatectomy;\n* Patients for whom good-quality imaging is available (CT scan and\u002For MRI and\u002For ultrasound);\n* Patients over 18 years of age;\n* Minimally invasive surgery by conventional or robot-assisted laparoscopy.\n\nExclusion Criteria:\n\n* Surgery by laparotomy",{"count":405,"type":22},40,"Multimodal intraoperative minimal-invasive (laparoscopic or robotic) liver surgery images will be registered to each other. Explicitly, these are the ultrasound and laparoscope images. Once they are registered, they will reveal the hidden tumor's location to the surgeon in real time through augmented reality. The intraoperative augmentation will also be enriched with the preoperative data (e.g., CT or MRI). This will simplify minimal invasive liver surgery, improve surgical safety and accuracy. It will also shorten hospital stays and contribute to an overall better quality of life for the patient, which in return will reduce the health-care costs.",[28,408],"Laparoscopy",[410,411,412,413,414,66,415],"Intraoperative","preoperative","multimodal data","registration","laparoscopy","augmented reality","2024-09-19",{"date":418,"type":37},"2024-09-20",{"date":420,"type":37},"2023-09-15",{"date":422,"type":22},"2026-01",{"name":424,"class":44},"Centre Hospitalier Universitaire de Saint Etienne",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":431,"sex":17,"minAge":53,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":441,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":45},"100534355","preoperative-sildenafil-administration-for-hepatectomy-100534355","NCT06237751","Preoperative Sildenafil Administration for Hepatectomy","Inclusion Criteria:\n\n* Patients undergoing hepatic resection\n* age from 18-85 years\n* Child-Pugh ≤B\n* ASA II-III\n* willing to join the trial.\n\nExclusion Criteria:\n\n* Pregnancy or Lactation\n* Known Allergy to any Medications used in the Study\n* Hemoglobin (Hb) \\\u003C 90 g\u002FL\n* Body Mass Index (BMI) \\> 35 kg\u002Fm2 or \\\u003C 18 kg\u002Fm2\n* Hypertension \\> 180 mmHg\n* Renal Impairment (Creatinine, Cr 178 µmol\u002FL)\n* Severe Cardiovascular Diseases including Active Coronary Artery Disease, Severe Valve Stenosis and Hypertrophic Obstructive Cardiomyopathy, History of Stroke Within Six Months.",true,"85 Years",{"count":434,"type":22},16,[25],"Hepatectomy is an important treatment for liver diseases, and bleeding is one of the most common complications during dissection of the liver parenchyma. The Control Low Central Venous Pressure (CLCVP) technique is currently one of the most important techniques to control intraoperative bleeding. It mainly consists of fluid restriction, position adjustment, and the use of vasodilators. However, these measures focus on decreasing CVP by reducing the volume of return blood, and less attention is paid to factors such as pulmonary vascular resistance and cardiac function. Sildenafil, known as Viagra, is currently used to treat erectile dysfunction and pulmonary hypertension in men. Its action inhibits phosphodiesterase-5 (PDE-5) and increases cGMP levels, leading to smooth muscle relaxation and vasodilation. Its pharmacological properties provide potential value for the treatment of many diseases. However, few studies have been conducted both domestically and internationally on the use of sildenafil citrate in liver resection related to CLCVP. This study aims to investigate the influence of preoperative oral administration of Sildenafil Citrate combined with IPM on IBL and surgical results during open or laparoscopic hepatectomy, as well as its safety and feasibility. It is expected to provide an innovative management optimization plan for reducing the bleeding in hepatectomy and to provide empirical support for the potential value of Sildenafil Citrate or Sildenafil-like drugs in improving the safety and quality of perioperative hepatectomy patients.",[438,28,439,440],"Central Venous Pressure","Hemodynamics Instability","Sildenafil",[442,28,408,443,444],"Sildenafil Citrate","Low central venous pressure","Study protocol","2024-06-25",{"date":447,"type":37},"2024-06-27",{"date":449,"type":37},"2024-02-01",{"date":451,"type":22},"2024-12-30",{"name":453,"class":44},"First People's Hospital of Chenzhou",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":462,"enrollmentInfo":463,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":45},"100552878","ambulatory-surgery-after-hepatectomy-monitoring-by-domomedicine-connected-tools-and-a-dedicated-nurse-100552878","NCT06478810","Ambulatory Surgery After Hepatectomy: Monitoring by Domomedicine Connected Tools and a Dedicated Nurse.","Ambulatory Surgery After Hepatectomy: Piloteasibility Study With Securing of the Post-operative Monitoring by Domomedicine Connected Tools and a Dedicated Nurse.","HEPADOM","Inclusion criteria : - Male or female, 18 to 69 years old\n\n* Indication for a minor laparoscopic hepatectomy (benign or malignant liver tumor, requiring resection of 1 or 2 segments maximum)\n* Membership in a social security system or beneficiary\n* Having given free and informed consent) Exclusion criteria : - Patient living alone and without anyone at home during the first 7 days at home\n* Patient unable to be escorted home by a responsible adult upon discharge\n* Non-French speaking patient\n* Uncompliant patient\n* Patient not reachable by phone\n* Home and convalescence site more than an hour's drive from the Paul Brousse Hospital Hepatobiliary Center\n* Women who have started a pregnancy or are breastfeeding\n* Previous hepatic surgery or supra-mesocolic surgery (exception: cholecystectomy)\n* Previous history of supra-umbilical parietal surgery (hernia\u002Fventricle)\n* Contraindication to laparoscopic approach\n* ASA score \\> 2\n* Cirrhosis (=F4 fibrosis suspected on Fibroscan or biopsy)\n* Coagulation disorder (platelets \\\u003C100 G\u002FL, INR \\>1.4), ongoing anticoagulant or antiaggregant treatment that cannot be suspended\n* Associated extrahepatic surgery (cholecystectomy allowed) or simultaneous radiofrequency destruction\n* Body mass index \\> 35kg\u002Fm2\n* Patient under guardianship, curatorship or safeguard of justice\n* Patient under AME (state medical aid)","69 Years",{"count":336,"type":22},[25],"There are public health expectations for the development of outpatient surgery and increased comfort and quality of care for the patient. In this study, we are interested in evaluating the feasibility of an outpatient hepatectomy with a a close and secure follow-up at home: through a connected platform and a follow-up by a nurse. The primary endpoint is the rate of re-hospitalization due to a postoperative complication before Day 30 and the rate of conversion to conventional hospitalization (= early failure of outpatient management). This single-center study will includes prospectively 20 patients requiring liver resection of up to 2 segments. The primary endpoint is the rate of re-hospitalization due to a postoperative complication before Day 30 and the rate of conversion to conventional hospitalization (= early failure of outpatient management).",[467,28],"Liver Tumor",[469,470,471],"Ambulatory surgery","Minor hepatectomy","Domomedicine follow-up","2024-06-24",{"date":447,"type":37},{"date":475,"type":22},"2024-09-01",{"date":477,"type":22},"2025-12-04",{"name":479,"class":44},"Assistance Publique - Hôpitaux de Paris",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":312,"enrollmentInfo":487,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":493,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":45},"100485584","adjuvant-stereotactic-body-radiotherapy-sbrt-for-hepatocellular-carcinoma-after-hepatectomy-with-narrow-margin-a-prospective-multi-center-randomized-controlled-open-labelled-phase-iii-study-100485584","NCT05602974","Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study","Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multicenter, Randomized Controlled, Open-labelled, Phase III Study","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Confirmed diagnosis of HCC. The diagnosis can be established radiographically by the criteria of the American Association for the Study of the Liver (AASLD), or by histologic diagnosis from the core biopsy;\n3. Pathologically confirmed as narrow margin (the shortest distance from the edge of the tumor to the surface of liver transection \\\u003C1cm) ;\n4. Child-Pugh class A and B7;\n5. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1;\n6. Willing to provide tissue from an excisional biopsy of a tumor lesion;\n7. For patients with active HBV: HBV DNA \\\u003C 2000 IU\u002FmL during screening, and have initiated anti-HBV treatment at least 7 days prior to SBRT and willingness to continue anti-HBV treatment during the study;\n8. Adequate organ and marrow function as defined below:\n\n1)Marrow: absolute neutrophil count ≥1.5×109\u002FL; platelets ≥50×109\u002FL; hemoglobin ≥90g\u002FL; 2)Liver: total bilirubin ≤3× institutional upper limit of normal (ULN); AST(aspartate aminotransferase) or ALT(alanine aminotransferase) ≤ 5× institutional ULN; albumin ≥29g\u002FL; 3)Kidney: creatinine ≤ 1.5× institutional ULN or estimated glomerular filtration rate (GFR) ≥50 mL\u002Fmin\u002F1.73 m2 (according to the Cockcroft-Gault formula); 9. Women of childbearing potential must be willing to use a highly effective method of contraception for the course of the study through 30 days after radiotherapy. Female patient of childbearing potential should have a negative serum pregnancy test before 72h of her first treatment. Sexually active males must agree to use an adequate method of contraception starting with the treatment through 4 months after radiotherapy.\n\nExclusion Criteria:\n\n1. Have received radiotherapy for the area to be treated in the past;\n2. Severe bleeding tendency or coagulation dysfunction within the previous 6 months;\n3. Extrahepatic metastasis;\n4. Known history of active Bacillus Tuberculosis (TB)\n5. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.\n6. Active infection requiring systemic therapy;\n7. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy;\n8. Known psychiatric or substance abuse disorders ;\n9. Pregnant or breastfeeding;\n10. Known history of human immunodeficiency virus (HIV: HIV 1\u002F2 antibodies);\n11. Received a live vaccine within 30 days before radiotherapy.",{"count":21,"type":22},[25],"Hepatocellular carcinoma (HCC) is the sixth prevalent malignancy worldwide. Although surgical excision is considered the standard treatment for resectable HCC, a high rate of postoperative recurrence was observed after partial hepatectomy, with a marginal recurrence rate up to 30%. Narrow margin resection may be the most appropriate procedure for centrally located HCC or HCC located near liver capsule because the premise for survival is the conservation of more normal liver parenchyma. Unfortunately, narrow margin resection has been reported to contribute to poor survival outcomes. However, no adjuvant therapy after hepatectomy is generally considered to be effective in reducing post-operative recurrence.\n\nRadiotherapy (RT) has been well used in many solid malignant tumors as an (neo)adjuvant to surgical treatment, including HCC. SBRT has shown encouraging rates of local control for HCC. Compared with standard fractionation radiation, SBRT can achieve more precise delivery of high-dose radiation beams to the lesion, obtaining a much smaller target volume. Meanwhile, it could be finished in a short period which can bring more convenience to patients. Recently, several study and randomized controlled trials revealed the survival benefit of adjuvant RT (IMRT and SBRT) in patients with HCC. A large-sample and high-quality multi-center, randomized controlled, prospective study is warranted to further confirm the efficacy of adjuvant radiotherapy in patients with narrow margin resection, considering the small sample size of above-mentioned studies.",[362,491,492,28],"Narrow Margin","Adjuvant Stereotactic Body Radiotherapy",[494,495,492,28],"Hepatocellular carcinoma","Narrow margin","2023-02-16",{"date":498,"type":37},"2023-02-17",{"date":500,"type":22},"2023-03-01",{"date":502,"type":22},"2027-12-01",{"name":504,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]